The PI3K – mTOR Pathway
How and why we target the PI3K and mTOR pathway in cancer
Pursuing first-in-class targeted therapies
The PI3K/mTOR pathway has been implicated in breast, prostate, endometrial, ovarian and hematological cancers, among others.
We are currently developing our lead drug candidate, gedatolisib, to treat advanced breast cancer and metastatic castration resistant prostate cancer.
Gedatolisib Pipeline
The safety and efficacy of investigational agents and/or investigational use of approved products have not been established. Ibrance® is a registered trademark of Pfizer, Inc. Nubeqa® is a registered trademark of Bayer AG. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PIK3CA, phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha; MT, mutated; HNSCC, head and neck squamous cell carcinoma; SCLC, squamous cell lung cancer; mCRPC, metastatic castration resistant prostate cancer.
Gedatolisib
Internal development of a pan-PI3K/mTOR inhibitor